Table 1.

Summary of ARVs Used for Optimization and Characterization of Drug-Loaded NPs

SI. No.	ARV	Abbreviation	Activity	Diameter (nm)	Zeta Potential (mV)	%Loading	%EE
1	Saquinavir	sQv	PI	56±1.8	21±1.9	1.5±2.1	14.8±42.0
2	Atazanavir	ATV	PI	60±2.6	25±0.8	ND	ND
3	Tenofovir	TDF	NRTI	58±2.3	22±0.3	ND	ND
4	Indinavir	IDV	PI	56±2.8	20±1.8	ND	ND
5	Ritonavir	RTV	PI	58±1.2	26±1.2	ND	ND
6	Zidovudine	ZDV	NRTI	56±1.2	24±0.5	ND	ND
7	Lopinavir	LPV	PI	58±1.9	24±0.1	ND	ND
8	Efavirenz	EFV	NNRTI	59±1.6	20±0.9	4.2±1.9	42±2.0
9	Darunavir	DRV	PI	58±1.5	21±10.3	8.3±2.0	83±2.0
10	Nevirapine	NVP	NNRTI	55±0.8	26±0.6	ND	ND
11	Lamivudine	3TC	NRTI	62±1.7	25±0.3	ND	ND
12	Fosamprenavir	FPV	Pl	55±1.7	23±2.5	ND	ND
13	Amprenavir	APV	PI	57±2.0	24±2.3	ND	ND
14	Dolutegravir	DTG	INI	60±8.5	24±1.4	0.13±0.8	1.3±0.9
15	Elvitegravir	EVG	INI	58±1.4	23±0.6	1.8±2.0	18.2±2.5
16	Cobicistat	CcosBl	PK Enhancer	70±2.1	27±0.8	ND	ND
17	Abacavir	ABC	NRTI	57±1.7	23±4.2	ND	ND
18	Emtricitabine	FTC	NRTI	56±1.4	24±2.1	ND	ND
19	Raltegravir	RAL	INI	65±1.8	26±0.5	0.07±0.01	0.8±0.8
20	Maraviroc	MVC	CCRS5 Inhibitor	65±2.4	24±0.5	ND	ND
21	Enfuvirtide	T20	Fusion Inhibitor	60±1.9	22±14	ND	ND
22	Delavirdine	DLV	NNRTI	56±1.4	19±0.8	0.74±1.0	7.4±1.2
23	Bictegravir	BIC	INI	57±1.4	29±1.4	0.48±0.9	4.9±1.2
24	Didanosine	ddl	NRTI	56±1.8	20±1.8	ND	ND
25	Zalcitabine	ddc	NRTI	62±1.7	22±2.3	ND	ND
26	Stavudine	d4T	NRTI	58±2.9	21±1.4	0.26±0.2	2.6±1.0

PI: Protease Inhibitor

INI: Integrase inhibitors

NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

NNRTI: Non-nucleoside reverse transcriptase inhibitors

ND: Not detectable by HPLC